scholarly journals The Impact of Clinical Trials on the Treatment of Diabetes Mellitus

2002 ◽  
Vol 87 (5) ◽  
pp. 1929-1937 ◽  
Author(s):  
David M. Nathan
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Trials ◽  
Treatment Of Diabetes ◽  
The Impact

Association and treatment of diabetes in patients affected by Covid-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1198-1201
Author(s):  
Syed Yasir Afaque
Keyword(s):  
Diabetes Mellitus ◽  
Prognostic Value ◽  
Heart Diseases ◽  
The Novel ◽  
The World ◽  
Treatment Of Diabetes ◽  
Coronavirus Infection ◽  
Composite Outcomes ◽  
Novel Coronavirus ◽  
The Impact

In December 2019, a unique coronavirus infection, SARS-CoV-2, was first identified in the province of Wuhan in China. Since then, it spread rapidly all over the world and has been responsible for a large number of morbidity and mortality among humans. According to a latest study, Diabetes mellitus, heart diseases, Hypertension etc. are being considered important risk factors for the development of this infection and is also associated with unfavorable outcomes in these patients. There is little evidence concerning the trail back of these patients possibly because of a small number of participants and people who experienced primary composite outcomes (such as admission in the ICU, usage of machine-driven ventilation or even fatality of these patients). Until now, there are no academic findings that have proven independent prognostic value of diabetes on death in the novel Coronavirus patients. However, there are several conjectures linking Diabetes with the impact as well as progression of COVID-19 in these patients. The aim of this review is to acknowledge about the association amongst Diabetes and the novel Coronavirus and the result of the infection in such patients.

scholarly journals Impact of timing of randomization after an acute coronary syndrome and subsequent events in patients with type 2 diabetes mellitus: an analysis of the EXAMINE trial

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Elharram ◽  
A Sharma ◽  
W White ◽  
G Bakris ◽  
P Rossignol ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Primary Outcome ◽  
Funding Source ◽  
Coronary Syndrome ◽  
The Impact

Abstract Background The timing of enrolment following an acute coronary syndrome (ACS) may influence cardiovascular (CV) outcomes and potentially treatment effect in clinical trials. Using a large contemporary trial in patients with type 2 diabetes mellitus (T2DM) post-ACS, we examined the impact of timing of enrolment on subsequent CV outcomes. Methods EXAMINE was a randomized trial of alogliptin versus placebo in 5380 patients with T2DM and a recent ACS. The primary outcome was a composite of CV death, non-fatal myocardial infarction [MI], or non-fatal stroke. The median follow-up was 18 months. In this post hoc analysis, we examined the occurrence of subsequent CV events by timing of enrollment divided by tertiles of time from ACS to randomization: 8–34, 35–56, and 57–141 days. Results Patients randomized early (compared to the latest times) had less comorbidities at baseline including a history of heart failure (HF; 24.7% vs. 33.0%), prior coronary artery bypass graft (9.6% vs. 15.9%), or atrial fibrillation (5.9% vs. 9.4%). Despite the reduced comorbidity burden, the risk of the primary outcome was highest in patients randomized early compared to the latest time (adjusted hazard ratio [aHR] 1.47; 95% CI 1.21–1.74) (Figure 1). Similarly, patients randomized early had an increased risk of recurrent MI (aHR 1.51; 95% CI 1.17–1.96) and HF hospitalization (1.49; 95% CI 1.05–2.10). Conclusion In a contemporary cohort of T2DM with a recent ACS, early randomization following the ACS increases the risk of CV events including recurrent MI and HF hospitalization. This should be taken into account when designing future clinical trials. Figure 1 Funding Acknowledgement Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Takeda Pharmaceutical

scholarly journals The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Zhuo Liu ◽  
Jing Gong ◽  
Wenya Huang ◽  
Fuer Lu ◽  
Hui Dong
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Trials ◽  
Theoretical Basis ◽  
Momordica Charantia ◽  
In Vivo Experiments ◽  
New Ideas ◽  
Treatment Of Diabetes ◽  
The Common

In recent years, many studies of Momordica charantia (MC) in the treatment of diabetes mellitus (DM) and its complications have been reported. This article reviewed the effect and mechanism of MC against diabetes, including the results from in vitro and in vivo experiments and clinical trials. The common side effects of MC were also summarized. We hope that it might open up new ideas for further mechanism exploration and clinical application as well as provide a scientific theoretical basis for the development of drugs or foods derived from MC.

Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review

2020 ◽  
Vol 30 (6) ◽  
Author(s):  
Ayu Wulan Dwiputri ◽  
Liza Pristianty ◽  
Andi Hermansyah
Keyword(s):  
Diabetes Mellitus ◽  
Southeast Asia ◽  
Pharmacist Intervention ◽  
Narrative Review ◽  
Patient Counselling ◽  
Treatment Of Diabetes ◽  
Pharmacist Services ◽  
The Impact

AbstractBackgroundThe growing burden of diabetes mellitus (DM) in Southeast Asia puts pharmacists in the ideal position to provide management of DM. This narrative review aims to describe the evidence of pharmacist contribution in improving DM in Southeast Asia.ContentA literature search was conducted to identify relevant research articles published from 2010 to 2018 in four databases (Scopus, Pubmed, MEDLINE, and Springerlink) describing pharmacist roles and activities intended to improve management of DM in Southeast Asian countries. Results were synthesized narratively and divided into three main sections: (1) the role of pharmacist in DM management, (2) the impact of pharmacist role, and (3) the barriers to the implementation of services in DM management. A total of 16 studies were identified, of which ten studies mentioned services that were conducted exclusively by a pharmacist and the remaining collaborated with other health professionals. A number of pharmacist services were reported including prevention, dispensing, medication review, drug information services, patient counselling and education, monitoring, follow-up, and referral. Barriers related to individual, organizational, and public recognition were described.Summary and outlookThe Pharmacist can contribute to improve DM management in a variety of settings. Action research on pharmacist intervention in DM is recommended.

scholarly journals AYURVEDIC MANAGEMENT OF DIABETES MELLITUS - A SINGLE CASE STUDY

2020 ◽  
Vol 8 (8) ◽  
pp. 4250-4253
Author(s):  
Pandey Mahesh H ◽  
Mule Pranita A
Keyword(s):  
Diabetes Mellitus ◽  
Single Case ◽  
Treatment Protocol ◽  
Blurred Vision ◽  
Current Case ◽  
Time Period ◽  
Incurable Illness ◽  
Treatment Measures ◽  
Treatment Of Diabetes ◽  
The Impact

Background: The study was intended to have a theoretical audit of the Madhumeha and its treatment spe-cifically to the utilization of a natural drug Phalatrikadi kwatha. Madhumeha, otherwise called Diabetes Mellitus is one of the sorts of Vataja prameha, that has been considered as an incurable illness (Ma-hagada). Because of extravagance in etiological components it brings about the inadequate arrangement of Kapha and Meda which further continues descending through the channels of Mutravaha srotas and get confined at Basti mukha prompting the side effects like Prabhoota mutrata (polyuria), Avila mutrata (tu-bidity of pee) and so on. As the disease is Chirakari, it requires a compelling treatment which can be pro-ceeded for quite a while with no evil impacts. Among the numerous treatment measures referenced, Phala-trikadi kwath has been chosen in this examination and the impact was assessed. Method: In the current logical examination a 53 years old Male directed in Outpatient having Objections of the patient was increased thirst, frequent urination, hunger, fatigue and blurred vision. By taking a gander at the signs and appearances of complaints of patient was resolved to have Diabetes after exhortation glucose tests reports. In the current case report lenient was required to treat with ayurvedic plan under the treatment of Diabetes. Going to the OPD of YMT Ayurvedic Hospital Kharghar and treated with preliminary medica-tion (Phalatrikadi kwatha). Patients were assessed in a time period for 15 days. FBS, PPBS with clinical sign and manifestations were tested. Result: In the wake of assessing the absolute impacts of the treatment, it was seen that Phalatrikadi kwath alongside diet and routine gave good alleviation. Conclusion: Significant result was observed with this treatment protocol in the management of Madhume-ha.

scholarly journals The impact of natural and synthetic polymers in formulating micro and nanoparticles for antidiabetic drugs

2020 ◽  
Vol 17 ◽  
Author(s):  
Nihad Al-hashimi ◽  
Mai Babenko ◽  
Maria Saaed ◽  
Negeen Kargar ◽  
Amr ElShaer
Keyword(s):  
Diabetes Mellitus ◽  
Biodegradable Polymers ◽  
Oral Delivery ◽  
Polymeric Materials ◽  
Serum Glucose ◽  
Antidiabetic Drugs ◽  
Nano Particles ◽  
Formulation Development ◽  
Treatment Of Diabetes ◽  
The Impact

: Diabetes mellitus is one of the long known chronic diseases, today over 400 million people are diagnosed with diabetes. Yet curing diabetes is a challenge. Over the decades, the approaches of treating diabetes mellitus have evolved and polymeric materials have played an integral part in developing and manufacturing anti-diabetic medications. However, injection of insulin remains the conventional therapy for the treatment of diabetes. Oral administration is generally the most preferred route; yet, physiological barriers lead to a challenge for the formulation development for oral delivery of antidiabetic peptide and protein drugs. This present review focuses on the role of different types of biodegradable polymers (e.g., synthetic and natural) that have been used to develop micro and nano particles based formulations for antidiabetic drugs (Type 1 and Type 2) and how the various encapsulation strategies impact its therapeutic effect, including pharmacokinetics studies, drug release profiles and efficacy of the encapsulated drugs. This review also includes studies of different dosage forms such as oral, nasal, inhalation and sublingual for the treatment of diabetes that have been investigated using synthetic and natural biodegradable polymers in order to develop an alternative route to subcutaneous route for a better control of serum glucose levels.

Sign in / Sign up

Export Citation Format

Share Document